Journal article
Experience with ponatinib in paediatric patients with leukaemia
Abstract
Ponatinib has proven to be effective in adults with Philadelphia chromosome-positive leukaemias, but data in paediatrics are scarce. Among paediatric patients with chronic myeloid leukaemia (n = 9) or acute lymphoblastic leukaemia (n = 12) treated with varying doses of ponatinib in 13 centres, 71% showed a decrease in disease burden after a median of three months. Ponatinib was well tolerated, with grade 3 toxicities occurring in 29% of …
Authors
Rossoff J; Huynh V; Rau RE; Macy ME; Sulis ML; Schultz KR; Burke MJ; Athale U; O'Brien MM; Gregory JJ
Journal
British Journal of Haematology, Vol. 189, No. 2, pp. 363–368
Publisher
Wiley
Publication Date
4 2020
DOI
10.1111/bjh.16338
ISSN
0007-1048